Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIB, Multi-center, Double-blind, Placebo-controlled, Parallel Group, 52-week Study to Evaluate the Safety and Efficacy of Certolizumab Pegol, Administered With DMARDs, in Patients With Low to Moderate Disease Activity Rheumatoid Arthritis
Brief Summary: To assess the clinical efficacy and safety of certolizumab pegol as add-on therapy with stable-dose disease-modifying antirheumatic drugs (DMARDs) for achieving clinical remission in patients with moderate to low disease activity rheumatoid arthritis


Options:
A: Arm Label: Certolizumab pegol 200 mg (CDP870); Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg (CDP870) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: methotrexate + adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Adalimumab | Arm Label: methotrexate + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): methotrexate + adalimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): methotrexate + placebo
C: Arm Label: CDP6038 60 mg sc every 2 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo iv | Arm Label: CDP6038 60 mg sc every 4 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo sc, Other: Placebo iv | Arm Label: CDP6038 120 mg sc every 2 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo iv | Arm Label: CDP6038 120 mg sc every 4 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo sc, Other: Placebo iv | Arm Label: CDP6038 240 mg sc every 2 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo iv | Arm Label: CDP6038 240 mg sc every 4 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo sc, Other: Placebo iv | Arm Label: Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Biological: Tocilizumab (Actemra or RoActemra), Other: Placebo sc | Arm Label: Placebo sc every 2 weeks plus methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo sc, Other: Placebo iv | Arm Label: Placebo sc every 4 weeks plus methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo sc, Other: Placebo iv | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 60 mg sc every 2 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 120 mg sc every 2 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 240 mg sc every 2 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: Tocilizumab (Actemra or RoActemra); Assigned to Arm(s): Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 60 mg sc every 4 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 240 mg sc every 4 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 120 mg sc every 4 weeks plus methotrexate | Intervention Type: OTHER; Name: Placebo sc; Assigned to Arm(s): Placebo sc every 2 weeks plus methotrexate, Placebo sc every 4 weeks plus methotrexate, Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate | Intervention Type: OTHER; Name: Placebo sc; Assigned to Arm(s): CDP6038 120 mg sc every 4 weeks plus methotrexate, CDP6038 240 mg sc every 4 weeks plus methotrexate, CDP6038 60 mg sc every 4 weeks plus methotrexate | Intervention Type: OTHER; Name: Placebo iv; Assigned to Arm(s): CDP6038 120 mg sc every 2 weeks plus methotrexate, CDP6038 120 mg sc every 4 weeks plus methotrexate, CDP6038 240 mg sc every 2 weeks plus methotrexate, CDP6038 240 mg sc every 4 weeks plus methotrexate, CDP6038 60 mg sc every 2 weeks plus methotrexate, CDP6038 60 mg sc every 4 weeks plus methotrexate, Placebo sc every 2 weeks plus methotrexate, Placebo sc every 4 weeks plus methotrexate
D: Arm Label: Group I: Placebo + Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Arm Label: Group II: Golimumab + Methotrexate (MTX); Type: PLACEBO_COMPARATOR; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: DRUG; Name: methotrexate (MTX); Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX)

Answer: A